16.3 Brain-Tissue Oxygen and Multimodality Monitoring (02.E–F)

ICP can look acceptable while the tissue is still hypoxic or metabolically starved. Multimodality monitoring adds oxygen, extraction, and chemistry to pressure and velocity so you can see secondary injury that a single channel misses. Independent OpenExamPrep teaching covers brain-tissue oxygen and related monitors as listed under diagnostic studies (02.E–F). It is not a claim that every patient needs every probe, and it is not a claim that oxygen-guided care has a proven mortality benefit.

Brain-tissue oxygen (PbtO2)

A PbtO2 probe (polarographic Licox-type or optical fluorescence devices) sits in white matter and reports local oxygen tension in mmHg. Placement is a clinical choice: uninjured frontal white matter as a more global-ish sample versus peri-lesional tissue if you care about a specific penumbra. After insertion there is a run-in period (often 30–120 minutes) before you trust the number. An oxygen challenge (transiently raising FiO2) that fails to increase PbtO2 suggests a dead probe, a hematoma at the tip, or non-viable tissue—not a reason to stack therapies blindly.

Normal-ish values in monitored ICU patients are often about 20–35 mmHg. Common teaching is to treat PbtO2 below 20 mmHg. Values in the low teens are more ominous; below about 10 mmHg is frequently called critical. The BTF 4th edition advanced-monitoring chapter is cautious: evidence is weaker than for ICP thresholds, and jugular desaturation below 50% is the Level III extraction number they highlight. Bedside protocols, including BOOST-style bundles, still operationalize 20 mmHg as the hypoxia line.

Low PbtO2 is a supply–demand mismatch, not a single diagnosis. Work through the list instead of giving one drug:

Worked example: ICP 12 mmHg, CPP 75 mmHg, PbtO2 11 mmHg, PaO2 52 mmHg. The oxygen problem is pulmonary until proven otherwise. Another: ICP 12 mmHg, CPP 75 mmHg, PbtO2 11 mmHg, PaO2 95 mmHg, and continuous EEG with nonconvulsive status epilepticus. Treat the seizures. A third: ICP 28 mmHg, CPP 52 mmHg, PbtO2 11 mmHg. Fix the pressure and perfusion first.

Jugular venous oxygen saturation (SjvO2)

A jugular bulb catheter samples blood near the origin of the internal jugular vein as a hemispheric mix of cerebral venous effluent (the dominant jugular is often the right). SjvO2 is commonly taught as 55–75%.

The BTF 4th edition lists jugular saturation <50% as a threshold to avoid (Level III) to reduce mortality and improve outcomes. SjvO2 is global-ish and can miss a focal ischemic island that a PbtO2 probe in that island would catch. It can also look falsely high if the catheter is not at the bulb. Confirm position on a lateral skull film or CT. Complications include carotid puncture, thrombosis, and infection—this is still a central line in a neck vein.

Cerebral microdialysis

A microdialysis catheter perfuses a semi-permeable membrane in brain extracellular fluid. Typical analytes are glucose, lactate, pyruvate, glycerol, and glutamate. The lactate/pyruvate (L/P) ratio is the ischemia/anaerobic flag:

• L/P >25 is often called abnormal.
• L/P >40 is the commonly taught anaerobic / metabolic crisis threshold, especially when brain glucose is low (many papers use brain glucose <0.2–0.7 mmol/L depending on the definition).
• Isolated lactate rise with a stable L/P can be hyperglycolysis rather than ischemia.
• Rising glycerol suggests membrane breakdown.
• Very low brain glucose may reflect ischemia or over-tight systemic glucose control; check the serum glucose before you celebrate a tight insulin drip.

Samples usually run hourly. Chemistry can worsen hours before infarction is visible on CT. That lead time is the point of the catheter, not a reason to ignore the examination.

Near-infrared spectroscopy (NIRS): know the limits

NIRS estimates regional oxy/deoxyhemoglobin and reports a saturation (rSO2 or similar). It is attractive because it is noninvasive and familiar from cardiac operating rooms. In the adult neuro ICU it is limited by:

• Extracranial contamination (scalp and skull blood)
• Uncertain path length through swollen or extra-axial collections
• Poor spatial coverage (two forehead stickers are not a whole-brain map)
• Weaker outcome validation than ICP or even PbtO2 protocols

Use NIRS as an adjunct trend, not as a reason to skip CT, TCD, or an indicated invasive monitor. A falling NIRS number with a stable arterial saturation should prompt a search for flow or ICP problems; it should not be treated as a stand-alone transfusion trigger.

BOOST-2 and BOOST-3: feasibility without mortality certainty

BOOST-2 (Okonkwo and colleagues, Critical Care Medicine 2017) was a phase 2 randomized trial of ICP-only versus ICP plus PbtO2-guided, tiered treatment in severe TBI, with PbtO2 values masked in the ICP-only arm. A management protocol based on both monitors reduced the proportion of time with PbtO2 <20 mmHg (about 0.45 in the ICP-only group versus 0.16 in the ICP plus PbtO2 group). ICP control was similar. The tiered protocol was feasible and safe in that trial. Outcome trends (mortality, good recovery) favored the oxygen arm, but the study was not powered for clinical efficacy. That sentence is the exam-safe summary: PbtO2-guided care can reduce hypoxia; it has not proven a mortality benefit.

BOOST-3 is the multicenter phase 3 comparative-effectiveness trial (SIREN network; protocol in BMJ Open) of ICP plus PbtO2-guided care versus ICP-guided care with PbtO2 masked. The operational goals in the protocol are ICP <22 mmHg and PbtO2 >20 mmHg. The primary outcome is Glasgow Outcome Scale–Extended at 6 months, not in-hospital death alone. As of this guide's writing date, do not overclaim that BOOST-3 has settled mortality. Smaller randomized comparisons and a 2025 meta-analysis of PbtO2 plus ICP versus ICP alone have not produced a statistically certain mortality reduction. Teach the physiology, teach the thresholds, and leave outcome certainty to the completed phase 3 result.

Integration: one patient, several channels

No monitor wins ties by itself. Read them together:

A coherent bundle sounds like this: ICP and CPP first (the only channels with strong BTF threshold language), then oxygen delivery (airway, PaO2, hemoglobin, temperature, seizures), then vessel-specific tools (TCD, angiography) when the syndrome is DCI or large-vessel failure, with microdialysis and NIRS as extras when your center uses them. Multimodality monitoring is a conversation among numbers, not a substitute for walking to the bedside.